JAZZ Jazz Pharmaceuticals plc
- Stocks
- Healthcare
- NASDAQ: JAZZ
Price (delayed)
$111.3
Market cap
$6.75B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.63
Enterprise value
$10.98B
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration
Highlights
The company's debt fell by 6% YoY
The revenue has grown by 4.5% YoY
The company's EPS has shrunk by 185% QoQ
Jazz Pharmaceuticals's net income has shrunk by 184% QoQ
Key stats
What are the main financial stats of JAZZ
Market
Valuations
Earnings
Shares outstanding
60.66M
Market cap
$6.75B
Enterprise value
$10.98B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.85
Price to sales (P/S)
1.67
EV/EBIT
N/A
EV/EBITDA
29.57
EV/Sales
2.69
Revenue
$4.09B
Gross profit
$3.63B
Operating income
-$291.3M
Net income
-$404.84M
EBIT
-$301.24M
EBITDA
$371.29M
Free cash flow
$1.27B
Per share
Balance sheet
Liquidity
EPS
-$6.63
EPS diluted
-$6.82
Free cash flow per share
$20.67
Book value per share
$60.14
Revenue per share
$66.78
TBVPS
$70.78
Total assets
$10.94B
Total liabilities
$7.24B
Debt
$5.42B
Equity
$3.71B
Working capital
$1.28B
Debt to equity
1.46
Current ratio
1.62
Quick ratio
1.15
Net debt/EBITDA
11.39
Margins
Efficiency
Dividend
EBITDA margin
9.1%
Gross margin
88.7%
Net margin
-9.9%
Operating margin
-7.1%
Return on assets
-3.5%
Return on equity
-10%
Return on invested capital
-4%
Return on capital employed
-3.4%
Return on sales
-7.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAZZ stock price
How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-0.7%
1 week
-3.65%
1 month
1.99%
1 year
-1.48%
YTD
-9.62%
QTD
4.88%
Financial performance
How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$4.09B
Gross profit
$3.63B
Operating income
-$291.3M
Net income
-$404.84M
Gross margin
88.7%
Net margin
-9.9%
The company's net margin has shrunk by 198% YoY and by 183% QoQ
Jazz Pharmaceuticals's net income has shrunk by 184% QoQ
The operating income has dropped by 152% year-on-year and by 149% since the previous quarter
JAZZ's operating margin has dropped by 150% year-on-year and by 149% since the previous quarter
Price vs fundamentals
How does JAZZ's price correlate with its fundamentals
Growth
What is Jazz Pharmaceuticals's growth rate over time
Valuation
What is Jazz Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.85
P/S
1.67
EV/EBIT
N/A
EV/EBITDA
29.57
EV/Sales
2.69
The company's EPS has shrunk by 185% QoQ
The price to book (P/B) is 20% lower than the 5-year quarterly average of 2.3 but 2.8% higher than the last 4 quarters average of 1.8
Jazz Pharmaceuticals's equity has decreased by 11% from the previous quarter
The price to sales (P/S) is 33% less than the 5-year quarterly average of 2.5 and 7% less than the last 4 quarters average of 1.8
The revenue has grown by 4.5% YoY
Efficiency
How efficient is Jazz Pharmaceuticals business performance
The company's return on assets has shrunk by 200% YoY and by 185% QoQ
The return on equity has dropped by 193% year-on-year and by 184% since the previous quarter
JAZZ's ROIC has shrunk by 153% QoQ and by 150% YoY
The company's return on sales has shrunk by 151% QoQ and by 151% YoY
Dividends
What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAZZ.
Financial health
How did Jazz Pharmaceuticals financials performed over time
The total assets is 51% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has plunged by 56% from the previous quarter and by 33% YoY
The company's current ratio has shrunk by 52% QoQ and by 32% YoY
The company's debt is 46% higher than its equity
Jazz Pharmaceuticals's debt to equity has increased by 13% QoQ but it has decreased by 4.6% YoY
Jazz Pharmaceuticals's equity has decreased by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.